AMH and bone cancer: Das et al. (2011) and Dolinko et al. (2018) found no significant difference in AFC levels between women with overall cancers (including breast cancer, gynecological cancer, hematologic cancer, gastrointestinal cancer, brain cancer, and bone cancer) and their control groups. Johnson et al. (2013) also found that cancer patients and control subjects did not differ in ovarian reserve markers. In contrast, a decreased serum AMH concentration was shown in women with gliomas (Nordan et al., 2020).